Centogene (NASDAQ:CNTG) announced its quarterly earnings results on Wednesday. The company reported ($1.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.49), Yahoo Finance reports. Centogene had a negative net margin of 14.29% and a negative return on equity of 50.71%. During the same quarter last year, the firm earned ($0.32) EPS. Centogene updated its FY 2021 guidance to EPS.
Centogene stock traded down $0.29 during trading on Friday, reaching $6.91. The stock had a trading volume of 121,416 shares, compared to its average volume of 54,262. Centogene has a 52-week low of $6.76 and a 52-week high of $14.00. The business has a 50 day moving average price of $9.82 and a 200 day moving average price of $10.26. The stock has a market cap of $137.23 million, a PE ratio of -4.35 and a beta of -2.11.
A number of research analysts recently weighed in on CNTG shares. Zacks Investment Research upgraded shares of Centogene from a “strong sell” rating to a “hold” rating in a report on Tuesday, November 9th. Robert W. Baird lifted their price objective on shares of Centogene from $13.00 to $15.00 and gave the company an “outperform” rating in a report on Wednesday, September 8th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $17.80.
Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. The company develops rare disease platform, a data repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs.
Read More: What is a back-end load?
Receive News & Ratings for Centogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centogene and related companies with MarketBeat.com's FREE daily email newsletter.